

## 2019-nCoV Spike protein RBD (K417N, E484K, N501Y) Catalog No: C19SD-G232H

SARS-CoV-2 (501Y.V2 variant) with mutations at the key sites in RBD (K417N, E484K, and N501Y) has severely affected regions of South Africa. MD simulation indicates that the combination of E484K, K417N, and N501Y results in the highest degree of conformational modifications of RBD when bound to hACE2, compared to either E484K or N501Y alone. As new variants displace the first-wave virus, it is pivotal to evaluate their transmissibility, virulence, and their possible tendency to escape antibody neutralization. SignalChem's Recombinant 2019-nCoV Spike protein S1 subunit, RBD (K417N, E484K, N501Y) (319-541) was expressed in CHO cells using a C-terminal his tag.

## **Unique Selling Points**





Stratech

stratech.co.uk/signalchem info@stratech.co.uk

**Biologically active** 

Strong binding to hACE2



Purity Determined by densitometry



Suitable for functional ELISA studies

Competitors







Biopharma developing Anti-Sars-CoV-2 therapies



Government research organizations



**Target Customers** 

Biotech companies research 501Y.V2 neutralization





Scientists developing diagnostic tests University researchers studying 501Y.V2 variant